SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

14 Jun 2024 Evaluate
Lupin has informed that it enclosed a Press Release regarding completion of an inspection by U.S. FDA of the Company’s Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations. 

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2419.20 77.05 (3.29%)
29-Jun-2026 15:20 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1874.00
Dr. Reddys Labs. 1375.10
Cipla 1452.10
Zydus Lifesciences 1120.75
Lupin 2419.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: